{
    "clinical_study": {
        "@rank": "153160", 
        "arm_group": [
            {
                "arm_group_label": "BI 425809 single rising dose", 
                "arm_group_type": "Experimental", 
                "description": "BI 425809 powder for oral solution (PfOS) in single rising doses"
            }, 
            {
                "arm_group_label": "BI 425809 Crossover", 
                "arm_group_type": "Experimental", 
                "description": "Bioavailability of BI 425809 PfOS"
            }
        ], 
        "brief_summary": {
            "textblock": "To investigate safety, tolerability, and pharmacokinetics of BI 425809 following single\n      rising doses of BI 425809 in healthy male volunteers; To explore dose proportionality of BI\n      425809 as oral drinking solution; To investigate relative bioavailability of BI 425809 oral\n      drinking solution fasted compared to BI 425809 tablet fasted and tablet fed"
        }, 
        "brief_title": "Safety, Tolerability, and Pharmacokinetics of Single Doses BI 425809", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Healthy male subjects\n\n          -  Age 18 to 45 years (incl.)\n\n          -  Body mass index (BMI) 18.5 to 29.9 kg/m2 (incl.)\n\n          -  Subject must be able to understand and comply with study requirements\n\n        Exclusion criteria:\n\n          -  Any finding in the medical examination (including blood pressure (BP), pulse rate\n             (PR) or electrocardiogram (ECG)) deviating from normal and judged clinically relevant\n             by the investigator\n\n          -  Repeated measurement of systolic blood pressure <90 or >140 mmHg, or diastolic blood\n             pressure <50 or >90 mmHg, or pulse rate <50 or >90\n\n          -  Any laboratory value outside the reference range that the investigator considers to\n             be of clinical relevance\n\n          -  Any evidence of a concomitant disease judged clinically relevant by the investigator\n\n          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,\n             immunological or hormonal disorders\n\n          -  Surgery of the gastrointestinal tract that could interfere with kinetics of the study\n             drug(s)\n\n          -  Diseases of the central nervous system (such as epilepsy), other neurological\n             disorders or psychiatric disorders"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02068690", 
            "org_study_id": "1346.1", 
            "secondary_id": "2013-004937-34"
        }, 
        "intervention": [
            {
                "arm_group_label": "BI 425809 single rising dose", 
                "description": "BI 425809 PfOS", 
                "intervention_name": "BI 425809 PfOS", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 425809 single rising dose", 
                "description": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 425809 Crossover", 
                "description": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 425809 Crossover", 
                "description": "BI 425809 tablet", 
                "intervention_name": "BI 425809 tablet", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 425809 Crossover", 
                "description": "BI 425809 PfOS", 
                "intervention_name": "BI 425809 PfOS", 
                "intervention_type": "Drug"
            }
        ], 
        "lastchanged_date": "May 19, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Ingelheim", 
                    "country": "Germany"
                }, 
                "name": "1346.1.1 Boehringer Ingelheim Investigational Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Safety, Tolerability, and Pharmacokinetics of Single Rising Oral Doses of BI 425809 in Healthy Male Subjects (Partially Randomised, Single-blind, Placebo-controlled) and Investigation of Relative Bioavailability and Food Effect of BI 425809 (Open-label, Randomised, Three-way Crossover)", 
        "overall_contact": {
            "email": "clintriage.rdg@boehringer-ingelheim.com", 
            "last_name": "Boehringer Ingelheim Call Center", 
            "phone": "1-800-243-0127"
        }, 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "frequency [N(%)] of subjects with drug related adverse events (AEs)", 
            "safety_issue": "No", 
            "time_frame": "up to 18 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02068690"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Cmax (maximum measured concentration of the analyte in plasma)", 
                "safety_issue": "No", 
                "time_frame": "up to 192 hours"
            }, 
            {
                "measure": "AUC0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)", 
                "safety_issue": "No", 
                "time_frame": "up to 192 hours"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}